CompanyGraph
Shanghai Aohua Photoelectricity Endoscope Co., Ltd.
688212 · SSE · China
aohua.comFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionP/E ratio is 240.17×, higher than 95% of its Medical Devices peers (median 31.47×)
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
3.81BCNY566.74M · vs all stocks (USD)
Trailing P/E
240.17xvs Medical Devices peers
Revenue (TTM)
787.64MCNY117.13M · vs all stocks (USD)
Profit Margin
2.01%vs Medical Devices peers
Beta
-0.3610xvs all stocks
52-Week Change
-43.70%vs all stocks
Market Capitalization
3.81BCNY566.74M · vs all stocks (USD)
Enterprise Value
4.00BCNY594.28M · vs all stocks (USD)
Trailing P/E
240.17xvs Medical Devices peers
Forward P/E
33.51xvs Medical Devices peers
Price to Sales (TTM)
4.93xvs Medical Devices peers
Price to Book (MRQ)
3.02xvs Medical Devices peers
Enterprise to Revenue
5.07xvs Medical Devices peers
Enterprise to EBITDA
85.05xvs Medical Devices peers
Gross Margin
71.63%vs Medical Devices peers
Profit Margin
2.01%vs Medical Devices peers
Return on Assets (TTM)
-0.20%vs Medical Devices peers
Return on Equity (TTM)
1.18%vs Medical Devices peers
Revenue (TTM)
787.64MCNY117.13M · vs all stocks (USD)
Revenue per Share (TTM)
6.21CNYUpdated Aug 21, 2026Quarterly Revenue Growth
11.10%vs Medical Devices peers
Gross Profit (TTM)
491.65MCNY73.11M · vs all stocks (USD)
EBITDA (TTM)
118.11MCNY17.56M · vs all stocks (USD)
Net Income (TTM)
15.81MCNY2.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-44.78%vs Medical Devices peers
Operating Cash Flow (TTM)
14.51MCNY2.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-47.55MCNY-7.07M · vs all stocks (USD)
Payout Ratio
66.67%vs Medical Devices peers
Minority Interest (Equity)
13.56MCNYFY2025 · Dec 31, 2025Revenue
773.87MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
269.00MCNYFY2025 · Dec 31, 2025Gross Profit
504.86MCNYFY2025 · Dec 31, 2025Operating Income
42.04MCNY6.25M · vs all stocks (USD)
Pre-tax Income
117.12KCNYFY2025 · Dec 31, 2025Income Tax Expense
-10.47MCNYFY2025 · Dec 31, 2025Net Income
10.59MCNYFY2025 · Dec 31, 2025EBIT
7.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
118.11MCNYFY2025 · Dec 31, 2025Research & Development
147.01MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
113.88MCNYFY2025 · Dec 31, 2025Other Operating Expenses
19.02MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.03MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.92MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
127.24MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
127.24MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
10.59MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
865.75KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-115.00MCNYFY2025 · Dec 31, 2025Free Cash Flow
-245.12MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
338.58MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
10.59MCNYFY2025 · Dec 31, 2025Other Non-cash Items
17.82MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-116.03MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.37MCNYFY2025 · Dec 31, 2025Capital Expenditures
-130.13MCNYFY2025 · Dec 31, 2025Purchase of Investments
-846.00MCNYFY2025 · Dec 31, 2025Sale of Investments
924.29MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-51.84MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
405.18MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-179.45MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-16.58MCNYFY2025 · Dec 31, 2025Other Financing Charges
-52.07MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
157.08MCNYFY2025 · Dec 31, 2025Shares Outstanding
134.67MSharesUpdated Aug 21, 2026Float Shares
87.56MSharesUpdated Aug 21, 2026% Held by Insiders
31.74%vs all stocks
% Held by Institutions
20.96%vs all stocks
Total Cash (MRQ)
376.73MCNY56.02M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.80CNYUpdated Aug 21, 2026Total Debt (MRQ)
395.59MCNY58.83M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3043xvs Medical Devices peers
Current Ratio (MRQ)
1.87xvs Medical Devices peers
Book Value per Share (MRQ)
9.55CNYUpdated Aug 21, 2026Total Assets
2.00BCNY296.94M · vs all stocks (USD)
Total Current Assets
1.09BCNYFY2025 · Dec 31, 2025Total Liabilities
670.42MCNYFY2025 · Dec 31, 2025Total Non-current Assets
902.23MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
120.74MCNYFY2025 · Dec 31, 2025Total Current Liabilities
549.68MCNYFY2025 · Dec 31, 2025Cash
339.57MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.30MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
341.86MCNYFY2025 · Dec 31, 2025Other Short-term Investments
50.01MCNYFY2025 · Dec 31, 2025Accounts Receivable
431.62MCNYFY2025 · Dec 31, 2025Inventory
229.37MCNYFY2025 · Dec 31, 2025Accounts Payable
164.83MCNYFY2025 · Dec 31, 2025Short-term Debt
300.64MCNYFY2025 · Dec 31, 2025Other Current Liabilities
400.93KCNYFY2025 · Dec 31, 2025Long-term Debt
39.61MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
42.40MCNYFY2025 · Dec 31, 2025Common Stock (Book)
134.67MCNYFY2025 · Dec 31, 2025Retained Earnings
141.11MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.33BCNY197.25M · vs all stocks (USD)
Treasury Stock
40.02MCNYFY2025 · Dec 31, 202552-Week Low
24.89CNYUpdated Aug 21, 202652-Week High
53.72CNYUpdated Aug 21, 202652-Week Change
-43.70%vs all stocks
Beta
-0.3610xvs all stocks
50-Day MA
28.27CNYUpdated Aug 21, 2026200-Day MA
37.87CNYUpdated Aug 21, 2026Avg 10-Day Volume
4.87MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.36MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.1200CNYUpdated Aug 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 240.17×, higher than 95% of its Medical Devices peers (median 31.47×)Significant
P/E ratio: 240.167Industry median: 31.47Industry P95: 200.906Peers compared: 102
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.11Receivables vs revenue divergence: 2.99
High gross margins eroded by operating costsNotable
Gross Margin: 0.72Profit Margin: 0.02
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -4.36
Altman Z-Score 4.24: safe zoneNotable
Altman Z-Score: 4.24
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Prime Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Hansen Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zeria Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Careray Digital Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Sihuan Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Hiteck Biological Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Sinobioway Biomedicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationMinimal Tax and Interest Drag
Mahindra Lifespace Developers Ltd.
1 interpretationMinimal Tax and Interest Drag
Prakash Industries Ltd.
1 interpretationMinimal Tax and Interest Drag